Discovering, Developing & Chemically Optimising Nucleic Acid Therapies for Precise Delivery to Undruggable CNS Targets
Europe’s oligonucleotide landscape is entering a pivotal growth phase. With the €21M launch of Aerska and major collaborations such as Novartis and SciNeuro, Lundbeck and Contera, and Secarna and Vect-Horus, European biopharma companies are rapidly advancing RNA-targeted approaches to address previously undruggable CNS diseases.
In response to this momentum, the inaugural Oligonucleotides for CNS Summit Europe will unite 60+ senior industry leaders for the first European forum dedicated exclusively to CNS-focused oligonucleotide therapeutics.
The summit delivers three days of highly technical, data-driven discussions addressing the challenges unique to CNS development, with insights into next-generation BBB delivery strategies beyond TfR1, advanced in vivo and iPSC models, novel chemistry and conjugation approaches, and translational strategies bridging preclinical data to clinical and regulatory success.
Now is the moment to connect, collaborate and shape the next wave of RNA-based CNS innovation as the field accelerates globally.
The conference was small and yet had so many interactive elements and opportunities for discussion and networking really made it a productive experience.
Nicole, Director, Neurobiology, Novo Nordisk
The meeting was great for networking, the panellists and presenters were all high calibre and the ensuing discussions very informative.
Fay, Senior Director, Asset Discovery, Apellis
The meeting was very interactive. The balance between the presentation and the roundtable discussion was really good. I learned a lot and made valuable connections as well.
Setsu, Senior Scientist, FUJIFILM
Testimonials from the 5th Oligonucleotide for CNS US Summit
Explore the Full Event Guide
- 3 days of highly technical, data-driven discussions addressing the challenges unique to CNS development
- Share easily with your team to assess and mobilise interest
- Preview 7+ sessions containing brand-new data at the first European forum dedicated exclusively to CNS-focused oligonucleotide therapeutics
- Hear exclusive content from 16+ expert speakers from GSK, Roche, Contera Pharma, and more
- Unmissable networking opportunities, including roundtable discussions and a poster session
Attending Companies Include
Speaker Spotlight!
We're delighted to announce that Farzaneh Salem, Associate Director, GSK will be presenting at the summit, speaking on 'Predictive Power of PBPK Models to Guide CNS Oligonucleotide PK & Cellular Targeting'.
The session will cover the development and validation of PBPK models for predicting in vivo CNS exposure, distribution, and cellular engagement. As well as characterising cell-type–specific targeting in the CNS through consideration of biological barriers, cellular diversity, and molecular design.
Want to see who else is speaking and what’s on the agenda? Checkout the Event Guide here.
Official Partner
Recently Booked On Companies Include
Explore Related Events
Explore the Agenda
Gain targeted insight into CNS oligonucleotide development, from BBB delivery and conjugation chemistry to translational modelling and clinical learning.
Partner With Us
Position your organisation at the centre of Europe’s CNS oligonucleotide ecosystem as it rapidly scales.
Join Biopharma Experts
Connect with senior CNS, RNA, and oligo leaders shaping the future of RNA-targeted neurological therapies.